No Detail Found!

Establishment of Doxorubicin Resistant Human Osteosarcoma Cell Lines

Author(s)
Zhen Li Department of Medical Oncology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, People's Republic of China
Suwei Dong Department of Orthopaedics, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, People's Republic of China
Abstract
Background: Osteosarcoma (OS) is the most frequent highly malignant primary bone tumour in children and adolescence. The underlying mechanisms of OS progression behind multi-drug resistance s was still not completely clear and needed to uncover the underlying mechanisms of chemoresistance to develop more effective therapeutic strategies. Objective: The purpose of this study is to establish drug resistance OS MG-63 and U2OS cells induced by DOX, which will support further investigation into the underlying mechanisms. Method: MG63 and U2OS cell lines were treated with repeated exposure to gradually increasing concentrations of doxorubicin. The IC50 value of doxorubicin resistance MG63 and U2OS and the parental cells were detected by MTT. Results: The IC50 value (1065±12.32 ng/ml for MG-63, 1417±15.28 ng/ml for U2OS) of doxorubicin resistance MG63 and U2OS were18.86 and 3.1-fold that for the parental cells (p < 0.001, both). Conclusion: Our established doxorubicin-resistant cell lines should be a useful tool for identifying new mechanisms of drug resistance and new drug targets in osteosarcoma.
Publication Details
Page(s) 111-113
DOI DOI not available
Published Journal: Journal of Pioneering Medical Sciences, Volume: 15, Issue: 4, Year: 2026

Request the full text from PASTIC

Keywords
Osteosarcoma, Drug resistance, Doxorubicin
References
Anderson M.E. . .. Update on survival in osteosarcoma.” Orthopedic Clinics of North America, 47(2016) : 283-292.
Luetke A. . .Osteosarcoma treatment - where do we stand? a state of the art review. ” Cancer Treatment Reviews, 40(2014) : 523-532.
Hawkins D.S.,Arndt C.A. .2003 .Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. ” Cancer, 98(11) : 2447-2456.
Mirabello L. . .Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance. Epidemiology and End Results Program.” Cancer, 115(2009) : 1531-1543.
Gill J.,Gorlick R. .2021 .Advancing therapy for osteosarcoma. ” Nature Reviews Clinical Oncology, 18(10) : 609-624.
Regan D.P. . .Losartan blocks osteosarcoma-elicited monocyte recruitment and combined with the kinase inhibitor toceranib, exerts significant clinical benefit in canine metastatic osteosarcoma. ” Clinical Cancer Research, 28(2022) : 662-676.
Morrow J.J,Khanna C. .2015 .Osteosarcoma genetics and epigenetics: emerging biology and candidate therapies. ” Critical Reviews in Oncogenesis, 20(3-4) : 173-197.
Benjamin R.S. .2020 .Adjuvant and neoadjuvant chemotherapy for osteosarcoma: a historical perspective. ” Advances in Experimental Medicine and Biology, 1257 : 1-10.
Hattinger C.M. . .Advances in emerging drugs for osteosarcoma. ” Expert Opinion on Emerging Drugs, 20(2015) : 495-514.
Thorn C.F. . .Doxorubicin pathways: pharmacodynamics and adverse effects. ” Pharmacogenetics and Genomics, 21(2011) : 440-446.
Lourda M. . .Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of clusterin/apolipoprotein. International Journal of Cancer, 120(2007) : 611-622.
Suwei D. .2015 .NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin. ” Journal of Hematology & Oncology, 120 : .
Rotondo R. .2022 .The sesquiterpene lactone cynaropicrin manifests strong cytotoxicity in glioblastoma cells U-87 MG by induction of oxidative stress. ” Biomedicines, 10(7) : .
Lage H. “ .2008 .An overview of cancer multidrug resistance: a still unsolved problem. ” Cellular and Molecular Life Sciences, 65(20) : 3145-3167.
Housman G. . .Drug resistance in cancer: an overview. ” Cancers, 6(2014) : 1769-1792.
Sharom F.J. “ . .The P-glycoprotein multidrug transporter. , 50(2011) : 161-178.
0

Citations

0

Downloads

16

Views